Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 12, 2015, Pages 1524-1527

  Gunther G ^a,b   Van Leth, F ^c   Altet, N ^d,e   Dedicoat, M ^f   Duarte, R ^g,h   Gualano, G ⁱ   Kunst, H ^f,j   Muylle, I ^k   Spinu, V ^l   Tiberi, S ^m,n   Viiklepp, P ^o   Lange, C ^a,b,p  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF NAMIBIA   (Namibia)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e INSTITUT UNIVERSITARI D'INVESTIGACIÓ EN ATENCIÓ PRIMÀRIA JORDI GOL   (Spain)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g Centro Hospitalar Vila Nova de Gaia Espinho   (Portugal)

^h UNIVERSITY OF PORTO   (Portugal)

ⁱ NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k Microbiology Lab   (Belgium)

^l Marius Nasta Institute of Pneumology   (Romania)

^m Reference Hospital for MDR and HIV TB   (Italy)

ⁿ BARTS HEALTH NHS TRUST   (United Kingdom)

^o NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^p KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Drug resistance; Europe; Extensively drug resistant tuberculosis; MDR TB; TB; Tuberculosis Network European Trials

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; EUROPE; FEMALE; HUMAN; IN VITRO STUDY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPUTUM SMEAR; SWEDEN; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; CLINICAL TRIAL; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY; STATISTICAL MODEL;

ADULT; ANTITUBERCULAR AGENTS; ETHAMBUTOL; ETHIONAMIDE; EUROPE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 84948957364     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0274     Document Type: Article

References (10)

1. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. EB 134/12. Geneva, Switzerland: WHO, 2014.
2. World Health Organization. Definitions and reporting framework for tuberculosis. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO, 2013.
3. Falzon D, Gandhi N, Migliori G B, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
4. World Health Organization & European Centers for Diseases Prevention and Control. Tuberculosis Surveillance and monitoringin Europe, 2014. Stockholm, Sweden: ECDC, 2014.
5. Günther G, van Leth F, Alexandru S, et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis 2015; 21: 409-416.
6. Lange C, Abubakar I, Alffenaar J W, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: update 2011. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
8. Diacon A H, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993
9. Bastos M L, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first-and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-1374
10. Cegielski J P, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049-1063.